pyrroles has been researched along with oxidopamine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL | 1 |
| Ariga, H; Iguchi-Ariga, S; Miyazaki, S; Nakano, M; Nunome, K | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Brocco, M; Mela, F; Millan, MJ; Morari, M | 1 |
| Arai, Y; Kikuchi, T; Mitazaki, S; Nakagawasai, O; Nakaya, K; Niijima, F; Onogi, H; Sato, A; Tadano, T; Tan-No, K | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG | 1 |
| Abbasnejad, M; Esmaeili-Mahani, S; Pasban-Aliabadi, H | 1 |
| Collins, LM; Foley, T; Goulding, SR; Mazzocchi, M; Morales-Prieto, N; O'Keeffe, GW; Sullivan, AM | 1 |
9 other study(ies) available for pyrroles and oxidopamine
| Article | Year |
|---|---|
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate | 1999 |
Pyrroloquinoline quinone prevents oxidative stress-induced neuronal death probably through changes in oxidative status of DJ-1.
Topics: Animals; Antioxidants; Ascorbic Acid; Blotting, Western; Cell Death; Cell Survival; Dose-Response Relationship, Drug; Female; Hydrogen Peroxide; Microtubule-Associated Proteins; Neurons; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxidopamine; Pregnancy; Protein Binding; Protein Deglycase DJ-1; Pyrroles; Quinolines; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Vitamin E | 2008 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome | 2010 |
p-Hydroxyamphetamine causes prepulse inhibition disruptions in mice: contribution of dopamine neurotransmission.
Topics: Animals; Benzazepines; Clozapine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Indoles; Injections, Intraventricular; Male; Mice; Mice, Inbred Strains; Oxidopamine; p-Hydroxyamphetamine; Piperazines; Piperidines; Pyridines; Pyrroles; Reflex, Startle; Salicylamides; Sensory Gating; Sympathomimetics; Synaptic Transmission | 2010 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity | 2015 |
Orexin-A Protects Human Neuroblastoma SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Neurotoxicity: Involvement of PKC and PI3K Signaling Pathways.
Topics: Benzophenanthridines; Calcium; Carbazoles; Cell Line, Tumor; Cell Survival; Chromones; Cyclooxygenase 2; HSP70 Heat-Shock Proteins; Humans; Intracellular Space; Membrane Potential, Mitochondrial; Morpholines; Neuroblastoma; Neuroprotective Agents; Neurotoxins; NF-E2-Related Factor 2; Orexin Receptors; Orexins; Oxidopamine; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Signal Transduction | 2017 |
Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Neurodegenerative Diseases; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrroles; Rats; Substantia Nigra | 2022 |